To overcome sotorasib resistance, some combination studies, such as sotorasib with carboplatin and pemetrexed, sotorasib with metformin, sotorasib with adavosertib, sotorasib with DCC-3116, have been explored in preclinical studies, and most of the studies underlined the autophagy regulation and apoptosis-mediated cell death of KRAS-mutated cancers (Barrios-Bernal et al., 2023a; Ghazi et al., 2024; Li Q. et al., 2024; Yoshioka et al., 2024; Yamamoto et al., 2025). Here, KRAS is linked to cancer.